Announcement of phase 3 clinical trial results
input 2024.10.30 13:34
input 2024.10.30 13:34
Views 71
Japan’s Shionogi Pharmaceutical announced that its coronavirus treatment drug Jokova showed an effect in preventing the COVID-19 virus. [사진=게티이미지뱅크]Japan’s Shionogi Pharmaceutical announced on the 29th (local time) that, as a result of a global phase 3 clinical trial, its COVID-19 treatment drug ‘Zokova‘ showed an effect in preventing infection in people who came into contact with the patient.
Shionogi Pharmaceutical evaluated whether the risk of infection would be reduced if people in contact with a COVID-19 infected person took Dzokova. Clinical trial participants were recruited from family members of infected patients, and 2,400 people participated in the United States, South America, Africa, and Asia.
Clinical trials showed that people who took Dzokova were less likely to develop symptoms than those who took a placebo. The explanation is that the rate of infection among family members who stayed with a person infected with COVID-19 has decreased statistically significantly.
“COVID-19 remains a significant public health challenge, and there are currently no oral antivirals approved for prevention,” said Simon Portsmouth, senior vice president of clinical development at Shionogi Pharmaceuticals. “We need to protect ourselves and those close to us if they become infected.” “A preventive approach is needed, and this data shows the potential for using Djokova as a preventative measure.”
Jokova is an oral antiviral drug developed through joint research between Japan’s Shionogi Pharmaceutical and Hokkaido University. It was used under emergency use approval in Japan in 2022, and was officially approved in March of this year.
In Korea, Ildong Pharmaceutical signed a joint development agreement for Djokova in 2021 and secured domestic production rights and distribution rights. Ildong Pharmaceutical applied for an ‘import item permit’ for Djokova to the Ministry of Food and Drug Safety in January of last year, but when the approval was not granted, it changed it to ‘manufacture and sale item permit’ in December and is awaiting the results. The industry expects the results to be released within the year.
Copyrightⓒ Honest knowledge for health. Comedy.com kormedi.com / Reproduction and redistribution, AI learning and use prohibited
